Bcl-xL Prevents Peritoneal Dialysis Solution-Induced Leukocyte Apoptosis
Author(s) -
Santamaría Beatriz,
Benito–Martin Alberto,
Ucero Alvaro Conrado,
Reyero Ana,
Selgas Rafael,
Ruiz–Ortega Marta,
Egido Jesús,
Ortiz Alberto
Publication year - 2008
Publication title -
peritoneal dialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.79
H-Index - 83
eISSN - 1718-4304
pISSN - 0896-8608
DOI - 10.1177/089686080802805s10
Subject(s) - peripheral blood mononuclear cell , apoptosis , bcl xl , peritoneal dialysis , medicine , microbiology and biotechnology , programmed cell death , inhibitor of apoptosis domain , peritonitis , immunology , cancer research , biology , caspase , in vitro , biochemistry
Conventional glucose-containing peritoneal dialysis solutions (PDS) with a high glucose degradation product content accelerate leukocyte apoptosis and impair peritoneal defense. Mononuclear cells are less sensitive than neutrophils to PDS-induced apoptosis, suggesting that they may express antiapoptotic molecules. Since apoptosis induced by PDS requires Bax, we explored the role of an antiapoptotic protein of the same family, Bcl-xL, in PDS-induced apoptosis in cultured peripheral blood mononuclear cells and monocytic THP-1 cells. In these cells, conventional PDS decreased the expression of Bcl-xL protein with a temporal pattern compatible with their lethal effect. Inhibition of Bcl-xL also induced mononuclear cell apoptosis. A cell-permeable TAT-BH4 peptide that contains the BH4 domain of Bcl-xL prevented mononuclear cell apoptosis induced by PDS. These data suggest that Bcl-xL protects mononuclear cells from apoptosis induced by bioincompatible PDS and that Bcl-xL-like molecules should be explored to prolong leukocyte survival and potentiate peritoneal defense during peritonitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom